A study from Yoshito's group demonstrated that a novel drug, C‐122, inhibits tumour growth in hepatocellular carcinoma through down‐regulation of TCF4 and downstream genes such as SPP1, AXIN2, MMP7, ASPH, CD24, ANXA1 and CAMK2N1.56 This evidence concerns the gene ANXA1 and hepatocellular carcinoma.